NewTimeSpace (newtimespace.com) News: On June 15, 2026, the semiconductor concept sector in the Hong Kong stock market continued to strengthen, with the share price of ASMPT (00522.HK) pulling up substantially. As of 1:44 PM, the company's share price was quoted at HK$199.300, up 8.97%.
NewTimeSpace News: June 15, 2026, CAFE DE CORAL H(00341.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 8.18 billion, decreased by 4.5% YoY
NewTimeSpace (newtimespace.com) News: The robotics concept sector surged as UBTECH (09880.HK) opened higher and rallied on June 15. As of 1:24 PM, the company's share price was quoted at HK$113.400, up 6.18%.
NewTimeSpace News: Zhaoke Ophthalmology Limited (06622.HK) announced that the Therapeutic Goods Administration (TGA) of Australia has accepted for review the registration application for its 0.02% Atropine Sulfate Eye Drops (Product Code: NVK002), a treatment for slowing the progression of myopia in children. The application is supported by results from the Company's Phase III clinical trials.
NewTimeSpace News: Beijing Zhipu Huazhang Technology Co., Ltd. (02513.HK) announced that it has launched its new-generation flagship model GLM-5.2. The model features a 1M long context and keeps leading performance in long-horizon tasks. It will be open-sourced under the MIT License. The model is expected to increase the call volume of the company's open platform and API business in the future.
NewTimeSpace News: June 12, 2026, MAJOR HLDGS(01389.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 52.76 million, decreased by 9.07% YoY
NewTimeSpace News: Genscript Biotech Corporation (01548.HK) announced that its associate company Legend Biotech presented the first proof-of-concept clinical data of LB2501, an investigational in-vivo CD19/CD20 dual-target CAR-T cell therapy, for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma at the 2026 EHA Annual Meeting. At higher dose levels, the overall response rate reached 100% and the complete response rate stood at 83.3%, with all responses sustained. No dose-limiting toxicity, serious adverse events or immune effector cell-associated neurotoxicity syndrome were reported.
NewTimeSpace News: TIGERMED(03347.HK) will spend CNY 175.37 million to repurchase 4.44 million shares on Jun 12, 2026.
NewTimeSpace News: HAIER SMARTHOME(06690.HK) will spend CNY 32.86 million to repurchase 1.55 million shares on Jun 12, 2026.
NewTimeSpace News: June 12, 2026, TAT HONG EQUIP(02153.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at CNY 581.72 million, decreased by 8.33% YoY
NewTimeSpace News: BAY AREA DEV (00737.HK) plans to issue in total 250 million shares by subscription, with estimated net proceeds of HKD 456 million.
NewTimeSpace News: VC HOLDINGS (00821.HK) plans to issue up to 65.86 million shares by placement, with estimated net proceeds of HKD 14 million.
NewTimeSpace News: Simcere Pharmaceutical Group Limited (02096.HK) announced that SIM0689, a self-developed PD-1/VEGF-targeted bispecific antibody, has obtained the clinical trial approval notice issued by the National Medical Products Administration. Clinical trials for advanced solid tumors are planned. By relieving tumor-induced immune suppression and inhibiting angiogenesis, SIM0689 has demonstrated prominent anti-tumor efficacy even at low doses in multiple humanized mouse efficacy models.
NewTimeSpace News: Mabwell (Shanghai) Bioscience Co., Ltd. (02493.HK) announced that the Investigational New Drug (IND) application for 6MW5311 Injection in hematologic malignancies (acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma) has been officially approved by the U.S. FDA. 6MW5311 is the world’s first TCE innovative drug authorized for clinical development targeting LILRB4/CD3.
NewTimeSpace News: WUXI APPTEC(02359.HK) will spend HKD 288.55 million to repurchase 2.3 million shares on Jun 12, 2026.
NewTimeSpace News: KINGDEE INT\'L(00268.HK) will spend HKD 8.24 million to repurchase 1.16 million shares on Jun 12, 2026.
